Previous Article | Next Article ![]()
Journal of Clinical Microbiology, March 2004, p. 1341-1344, Vol. 42, No. 3
0095-1137/04/$08.00+0 DOI: 10.1128/JCM.42.3.1341-1344.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Division of Molecular Medicine, Rudjer Boskovic Institute,1 Department of Obstetrics and Gynaecology, Medical School,2 Department of Physics, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia3
Received 26 July 2003/ Returned for modification 8 September 2003/ Accepted 17 November 2003
|
|
|---|
|
|
|---|
Latent HPV infection is found in approximately 40% of young women, but only 1% of high-risk HPV-positive cervices (or fewer) will develop cervical cancer (2). Since only a small fraction of HPV-infected women develop cervical cancer, additional risk factors are likely to be important determinants of disease development. These factors could include hormonal factors, other sexually transmitted infections, tobacco smoking, and dietary factors (4).
It is still unclear whether other infectious agents contribute to increased cervical cancer risk. A history of multiple genital infections is more common in women with cervical cancer (8), suggesting that these agents might increase the risk of developing cancer. However, the possibility that their presence may be an indicator of sexual activity and hence a surrogate marker of oncogenic HPV infection cannot be excluded.
Most adults (80 to 90%) are infected with adeno-associated virus (AAV) (9), which is commonly carried in the genital region (11). AAV is a human helper virus-dependent parvovirus with the ability to suppress the oncogenic phenotype of a variety of viruses and oncogenes. From in vitro studies, AAV has been shown to prevent the replication of HPVs and therefore may protect infected patients from cervical intraepithelial neoplasia (CIN) (13). However, in vivo studies of women with cervical HPV infection or CIN gave inconsistent results regarding the role of AAV in cervical carcinogenesis (16, 20).
Human cytomegalovirus (HCMV), a widespread human herpesvirus, has been shown to induce cervical neoplasia in mice (12), to morphologically transform human cells in culture (15), and to cause persistent infections of the genitourinary tracts of women (6). However, HCMV DNA is not detected in most transformants and the mechanism by which HCMV might contribute to oncogenesis is still unclear.
The aim of this retrospective study was to determine whether infection with AAV and/or HCMV influences the already established oncogenic impact of HPV infection on CIN development in general and during pregnancy, which is often associated with the reactivation of latent viral infections.
Two groups of young women with CIN grades I to III (cytological diagnosis) were enrolled in this study: 165 nonpregnant women (mean age, 26.7 years; 37 women with CIN I, 65 with CIN II, and 63 with CIN III) and 53 pregnant women (mean age, 25.8 years; 23 women with CIN I, 14 with CIN II, and 16 with CIN III). For nonpregnant women, cervical specimens were collected during regular gynecological examinations with the standard cyto-brush, and for pregnant women, a cotton swab was used. Samples were placed in sterile phosphate-buffered saline (pH 7.2) and frozen at -20°C until DNA extraction was carried out (10). PCR conditions for HPV amplification have previously been described (10). A nested-PCR approach with two sets of primers complementary to the early regulatory region of the HCMV genome was applied for the detection of HCMV (3). AAV type 2 (AAV 2) was detected by two different approaches: one-step PCR (11) and nested-PCR amplification (18).
HPV, AAV 2, and HCMV were found in, respectively, 67, 6, and 4.1% of the 218 women (Table 1). For nonpregnant women with CIN I to III, 35.1, 64.6, and 81% of the samples, respectively, were HPV positive. Increased HPV infection was strongly associated (P < 0.001) with a higher CIN grade in the group of nonpregnant women. For pregnant women with CIN I to III, 60.9, 92.9, and 81.2% of the samples, respectively, were HPV positive. There was no statistically significant correlation between HCMV or AAV 2 infection and a higher CIN grade for either nonpregnant or pregnant women.
|
View this table: [in a new window] |
TABLE 1. Prevalences of different viral infections among nonpregnant and pregnant women and correlations between viral infections and CIN status in different study groups
|
There was no statistical correlation between HPV and AAV 2 or HCMV infections among either nonpregnant women or pregnant women. All but one of the AAV 2-positive samples (12 of 13 samples) were also HPV positive (odds ratio = 6.358). HCMV was present in 5.9% (4 of 68) of the HPV-negative samples and in 3.5% (5 of 141) of the HPV-positive samples.
There was a significant increase (P < 0.001) of all HPV types except low-risk HPV 6 and 11 with increasing CIN grade among nonpregnant women (Fig. 1A). The frequencies of different HPV types among pregnant women were incoherent (Fig. 1B).
![]() View larger version (27K): [in a new window] |
FIG. 1. Distributions of different HPV genotypes among nonpregnant (A) and pregnant women (B) according to CIN grade.
|
A contradictory role of AAVs in cervical cancer has been reported in the last few decades (7, 16). Although several epidemiological studies showed a negative association of AAVs with HPV-associated cervical cancer, some studies did not find AAVs in the cervix at all (16).
Han et al. (11) detected AAV in 50% of cervical samples of healthy patients by means of PCR, indicating that AAV is commonly carried in the genital tract and can be sexually transmitted. Walz et al. (19) showed that HPV could act as an AAV helper virus. In our study, 92.3% (12 of 13) of the AAV 2-positive samples were also HPV positive, pointing to a role for HPV as AAV 2 helper virus.
Several collective studies suggest that AAV 2 could be directly related to the suppression of the oncogenic role of HPV infection in cervical oncogenesis (9, 13). In the present study, we found AAV 2 in only 6% (13 of 218) of cervical specimens from women with CIN, while Walz et al. (20) detected AAV in 63% of biopsy samples from subjects with high-grade CIN. On the other hand, Strickler et al. (16) did not detect any AAV 2 in cervical specimens and also found no relationship between AAV antibodies and the presence or grade of neoplasia. In a study by Lanham et al. (14), AAV was found in similar proportions of high- and low-grade CIN samples. These findings provide no evidence that AAV infection plays a role in cervical tumorigenesis.
Ahn et al. (1) found no significant difference between AAV 2 prevalences in microdissections with CIN I to III and those in adjacent normal tissues, supporting the notion that AAV 2 is not associated with cervical tumorigenesis. Our findings are in concordance with that study, since no association between AAV 2-positive women and CIN grade was found.
A study by Erles et al. (9) showed that pregnant women are significantly more frequently seropositive for AAV than nonpregnant controls are, suggesting a reactivation of latent AAV in specific hormonal conditions and slight immunosuppression. Similar results were found in the present study; AAV 2 was more frequent in pregnant women than in nonpregnant women (20.5 versus 2.4%). Thus, AAV could be considered to be protective against CIN progression only during pregnancy.
Chan et al. (5) detected HCMV in 9.5% of cervical samples. However, there was no association between HCMV detection and cervical lesions or between HPV status and HCMV positivity, indicating that HCMV is most probably a bystander rather than a cofactor in cervical cancerogenesis. This finding could also explain why there was a low HCMV positivity rate for cervical samples (4.1%) in our study.
Thompson et al. (17) studied the role of HCMV in the development of cervical carcinoma. As expected, 86.4% of cervical cancer biopsy specimens were HPV positive by PCR, in comparison to only 3.9% of the samples being HCMV positive. No unusual histological diagnosis or more aggressive clinical behavior was observed in HCMV-positive samples, which led to the conclusion that HCMV is not associated with cervical cancer. Our results are in accordance with that study, since HCMV infection was detected in only 4.1% of the women in our study group and no statistical correlation between HCMV infection and increasing CIN grade was found.
Our findings indicate that HCMV and AAV 2 infections did not contribute to an increase or decrease in the grade of CIN. However, there was a marked increase in the AAV 2-positive rate among pregnant women compared to that among nonpregnant women in all CIN groups. A similar outcome was found for HPV, but only among women with CIN II; no such outcome was observed for HCMV.
Our results confirm the already established role of HPV in CIN development. Furthermore, these results provide no evidence that AAV 2 and HCMV infections have any impact on CIN development. HCMV is probably mostly a transient sexually transmitted infection, whereas HPV infection is usually persistent. Our data point out that HPV could indeed be an AAV helper virus and that AAV as such can be considered sexually transmissible.
We thank Jasminka Golubic for expert technical assistance. We are grateful to J. R. Schlehofer for helpful advice and for providing us with AAV 2 DNA.
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»